When the late-breaking abstracts from the European Society for Medical Oncology meeting in Madrid were released early last week, one of the more eagerly pored-over readouts was for Johnson & Johnson’s MARIPOSA study of its bispecific antibody product targeting EGFR and MET, Rybrevant, in non-small cell lung cancer (NSCLC).
ESMO 2023: Will J&J’s Rybrevant Be Able To Scale The Tagrisso Mountain?
Scrip talked to Johnson & Johnson’s vice president of oncology global medical affairs, Mark Wildgust, about how the healthcare giant hopes to plant a flag on Tagrisso’s mountain with its trio of Phase III butterfly-themed studies for the bispecific antibody Rybrevant presented at ESMO.
